Yi-Ting Liu
Overview
Explore the profile of Yi-Ting Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu W, Liu Y, Li J, Wang Y, Sun X, Hua M, et al.
Toxicol In Vitro
. 2024 Jun;
99:105867.
PMID: 38848824
Pristimerin (Pris), a bioactive triterpenoid compound extracted from the Celastraceae and Hippocrateaceae families, has been reported to exhibit an anti-cancer property on various cancers. However, the effects of Pris on...
2.
Zou J, Li S, Wang L, Zhou N, Ran J, Yang X, et al.
Int J Gen Med
. 2024 Jun;
17:2527-2538.
PMID: 38841128
Background: Emerging evidence suggests that systemic inflammatory and nutritional biomarkers, along with derived indices, could serve as predictors for sarcopenia in cancer population. This study aimed to compare these predictors,...
3.
Chang C, Tsai C, Liu Y, Endo Y
Phys Chem Chem Phys
. 2024 Jan;
26(6):4922-4928.
PMID: 38263876
Pure rotational transitions of the ClSO radical have been observed by Fourier-transform microwave spectroscopy. a-type and b-type transitions, for both Cl and Cl isotopologues, were detected, and the observed very...
4.
Liu Y, Chang C, Nakajima M, Endo Y
Phys Chem Chem Phys
. 2023 Dec;
25(48):33112-33118.
PMID: 38044842
Pure rotational transitions of two conformers of the CHCHCO radical have been observed by Fourier-transform microwave spectroscopy, where one conformer is called the s--3-propenalyl radical and the other the 3-propenolyl...
5.
Chien H, Li C, Su W, Chang K, Chen C, Liu Y, et al.
Life Sci
. 2023 Jul;
330:121855.
PMID: 37419413
Brain cancer is a deadly disease with low survival rates for over 70 % of patients. Therefore, there is a critical need to develop better treatment methods and strategies to...
6.
Liu Y, Cheng Y, Shao D
Clin Nucl Med
. 2023 Jun;
48(9):e434-e435.
PMID: 37385219
Primary cardiac chondrosarcoma invading the right pulmonary vein is very rare, whereas secondary cardiac chondrosarcoma is relatively common. We reported the 18 F-FDG PET/CT findings of primary cardiac chondrosarcoma and...
7.
Peng C, Wang S, Hwang Y, Sun W, Chiu L, Liu Y, et al.
RSC Adv
. 2023 May;
13(22):14878.
PMID: 37200692
[This corrects the article DOI: 10.1039/D3RA01927F.].
8.
Peng C, Wang S, Hwang Y, Sun W, Chiu L, Liu Y, et al.
RSC Adv
. 2023 May;
13(19):13169-13176.
PMID: 37124006
CuI-mediated cyclization methodology helped yield benzimidazoles with different substitution manner, such as 1,2-diarylbenzimidazoles (4 and 5) and 1-arylbenzimidazoles (6-15). The result of structure-activity relationship (SAR) study confirmed the significance of...
9.
Chang C, Chao M, Lee H, Liu Y, Tu H, Lien S, et al.
J Enzyme Inhib Med Chem
. 2023 Jan;
38(1):2166039.
PMID: 36683274
Inhibiting a specific target in cancer cells and reducing unwanted side effects has become a promising strategy in pancreatic cancer treatment. MAP4K4 is associated with pancreatic cancer development and correlates...
10.
Qiao M, Li Y, Yang Y, Pang C, Liu Y, Bian C, et al.
Eur J Med Chem
. 2022 Dec;
247:115047.
PMID: 36586297
Developing non-statin small molecules for the treatment of hypercholesterolemia remains challenging. The proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapies have attracted considerable attentions. Forty-five 7030B-C5 derivatives were synthesized and evaluated...